RELATED CONTENT
NEWS
- Roche to phase out microarray offering to focus on genome sequencing
- Illumina's "impressive" Q1 resurrects Roche rumors
- Abbott to collaborate with Janssen Biotech and Pharmacyclics on CLL companion diagnostic
- Illumina back on Roche's shopping list? $60 per share could seal the deal

